Bristol Myers Squibb (CELG-RI) Non-Current Debt (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has 18 years of Non-Current Debt data on file, last reported at $42.2 billion in Q1 2026.

• Non-Current Debt for Q1 2026 came in at $42.2 billion, down 8.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $42.2 billion (down 8.68% YoY), and the FY2025 annual result was $42.8 billion, down 9.98% from the prior year.
• Non-Current Debt fell to $42.2 billion in Q1 2026 per CELG-RI's latest filing, from $42.8 billion in the prior quarter.
• Over five years, Non-Current Debt peaked at $49.5 billion in Q1 2024 and troughed at $32.1 billion in Q3 2023.
• A 5-year average of $41.2 billion and a median of $42.2 billion in 2026 frame the typical range for Non-Current Debt.
• The sharpest annual moves came in 2022 and 2024: Non-Current Debt slipped 15.85% in 2022, then surged 51.46% in 2024.
• A 5-year view of Non-Current Debt shows it stood at $35.1 billion in 2022, then rose by 4.56% to $36.7 billion in 2023, then grew by 29.87% to $47.6 billion in 2024, then slipped by 9.98% to $42.8 billion in 2025, then fell by 1.63% to $42.2 billion in 2026.
• Business Quant data shows CELG-RI's Non-Current Debt at $42.2 billion in Q1 2026, $42.8 billion in Q4 2025, and $44.5 billion in Q3 2025.